185 related articles for article (PubMed ID: 37224601)
21. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
Covino DA; Desimio MG; Doria M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
[TBL] [Abstract][Full Text] [Related]
22. Reactivation of latent HIV by histone deacetylase inhibitors.
Shirakawa K; Chavez L; Hakre S; Calvanese V; Verdin E
Trends Microbiol; 2013 Jun; 21(6):277-85. PubMed ID: 23517573
[TBL] [Abstract][Full Text] [Related]
23. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
24. The Current Status of Latency Reversing Agents for HIV-1 Remission.
Rodari A; Darcis G; Van Lint CM
Annu Rev Virol; 2021 Sep; 8(1):491-514. PubMed ID: 34586875
[TBL] [Abstract][Full Text] [Related]
25. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
26. Impact of latency-reversing agents on human macrophage physiology.
Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
Immun Inflamm Dis; 2023 Jan; 11(1):e590. PubMed ID: 36480653
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 Antagonist Obatoclax Reactivates Latent HIV-1 via the NF-κB Pathway and Induces Latent Reservoir Cell Apoptosis in Latently Infected Cells.
Zhou C; Li T; Xia M; Wu Z; Zhong X; Li A; Rashid HK; Ma C; Zhou R; Duan H; Zhang X; Peng J; Li L
ACS Infect Dis; 2023 Nov; 9(11):2105-2118. PubMed ID: 37796279
[TBL] [Abstract][Full Text] [Related]
29. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
[TBL] [Abstract][Full Text] [Related]
30. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
[TBL] [Abstract][Full Text] [Related]
31. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
[TBL] [Abstract][Full Text] [Related]
33. Modeling HIV-1 Latency Using Primary CD4
Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
[TBL] [Abstract][Full Text] [Related]
34. A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway.
Lu W; Yang C; Xu X; Chen C; Hou X; Fang H; Liu S
Life Sci; 2021 Feb; 267():118427. PubMed ID: 32941894
[TBL] [
